CD274 and non-small cell lung carcinoma: Recent economic evaluations raised a controversy that pembrolizumab is more cost‐effectiveness than chemotherapy in the first‐line treatment of advanced NSCLC with high‐level PD‐L1 expression.22, 23, 24